UGT2B17 and prostate carcinoma: In men, UGT2B15(D85Y) and the UGT2B17 deletion were both associated with alterations in serum steroid levels and fat mass (23, 57, 58) and the UGT215(D85Y) variation (56, 59) has been reported to be associated with increased prostate cancer risk in unselected (59), Caucasian (60) and Japanese (61) subjects.